News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

28

December

2022

Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
Read More
21

December

2022

Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute
Read More
15

December

2022

Israeli Biotech Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders
Read More
13

December

2022

Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
Read More
9

December

2022

Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute
Read More
23

November

2022

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial
Read More
17

November

2022

Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
Read More
11

October

2022

Clearmind Medicine Featured in "Psychedelics Tonight," Streaming on ALTRD.TV
Read More
22

September

2022

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome
Read More
24

August

2022

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment
Read More
21

June

2022

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine
Read More
15

June

2022

Clearmind Medicine Appoints New Chief Financial Officer
Read More
7

June

2022

Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment
Read More
2

June

2022

Clearmind Medicine and SciSparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment
Read More
1

June

2022

Clearmind Medicine Granted Patent Approval for Psychedelic-Based Alcohol Substitute in India
Read More